Vimta Labs Limited will hold its 35th Annual General Meeting (AGM) on Friday, 06th June 2025 at 10:00 a.m. (IST) through Video Conferencing.
The company is providing remote e-voting facility before and during the AGM.
Cut-off date for voting and record date for dividend payment is Friday, 30th May 2025.
Remote e-voting commences on Tuesday, 03rd June 2025 at 09:00 a.m. (IST) and ends on Thursday, 05th June 2025 at 05:00 p.m. (IST).
Payment of Dividend, if approved, will be done on Monday, 16th June 2025.
The AGM includes ordinary business such as:
Approving the audited financial statements for the year ended 31st March 2025.
Declaring a dividend of ₹ 2/- per equity share for the financial year ended 31st March 2025.
Re-appointing Mr. Satya Sreenivas Neerukonda as an Executive Director.
Special business includes:
Ratification of remuneration of cost auditors for financial year ending 31st March 2026 with a remuneration of ₹ 50,000 plus GST to M/s Lavanya & Associates.
Appointment of M/s D Hanumanta Raju & Co as Secretarial Auditors for five consecutive financial years commencing from the conclusion of the 35th AGM until the conclusion of the 40th AGM to be held in the year 2030.
Issue of Bonus Shares in the proportion of 1:1 i.e., 1 (One) bonus equity share for every 1 (One) existing fully paid-up equity share held by the Members of the Company.
Re-appointment of Dr. Yadagiri R Pendri as an Independent Director for a second and final term of five years commencing from 10th August 2025 to 09th August 2030.
Approval for revision of remuneration payable to Ms. Harita Vasireddi (Managing Director), Mr. Harriman Vungal (Executive Director – Operations) and Mr. Satya Sreenivas Neerukonda (Executive Director).
Increase in Overall Borrowing Limits of the Company to ₹ 300 Crores.
Increase in Overall Limits for Disposal or Encumbrance of Company’s Undertakings to ₹ 300 Crores.
Addition of New Objects in the Objects Clause of the Memorandum of Association of the company related to Contract Research and Development Activities (CDMO) and research and development of biologics, biosimilars, peptides and complex generics.